Breaking News Instant updates and real-time market news.

TWX

Time Warner

$99.89

0.69 (0.70%)

, SNAP

Snap

$17.33

-0.2112 (-1.20%)

11:34
06/19/17
06/19
11:34
06/19/17
11:34

Time Warner signs $100M deal with Snap for shows, ads, WSJ says

Time Warner's (TWX) Turner cable channels and Warner Bros. studio will develop up to ten original shows a year for Snap (SNAP) as part of a $100M two-year deal, the Wall Street Journal reports, citing comments made by Gary Ginsberg, Time Warner's executive VP of corporate marketing and communications. The deal also includes a path for Time Warner's HBO to create shows for Snap and advertising commitments from HBO, Warner Bros. and Turner networks. Reference Link

TWX

Time Warner

$99.89

0.69 (0.70%)

SNAP

Snap

$17.33

-0.2112 (-1.20%)

  • 28

    Jun

  • 19

    Jul

TWX Time Warner
$99.89

0.69 (0.70%)

04/20/17
PIVT
04/20/17
DOWNGRADE
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold saying shares are trading near the value of AT&T's (T) offering price.
04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/17
OPCO
04/24/17
NO CHANGE
OPCO
Sprint, DISH the only assets for sale, says Oppenheimer
Oppenheimer analyst Timothy Horan noted that wireless companies will be allowed to discuss M&A, and says he sees Sprint (S) and possibly DISH (DISH) as the only assets for sale. The analyst believes the most likely outcome is for consolidation around the four major wireless providers, something along the lines of Charter (CHTR)/Sprint, T-Mobile (TMUS)/Comcast (CMCSA; CMCSK), Verizon (VZ)/DISH, with AT&T's (T) position "fairly solidified" with DirectTV/Time Warner (TWX). Further, Horan suspects Sprint will be sold first, most likely to Charter, although T-Mobile is a possibility and could be the controlling company/management and likely paying a premium for Sprint.
05/03/17
05/03/17
DOWNGRADE

Hold
Wunderlich downgrades Charter on valuation, sees some level of M&A priced in
As previously reported, Wunderlich analyst Matthew Harrigan downgraded Charter (CHTR) to Hold from Buy, citing valuation. He thinks that the current stock price imbeds some expectation for merger activity, apart from an eventual collapse of the Liberty Broadband (LBRDA) and Liberty Ventures (LVNTA) ownership structure, he tells investors. While a theoretical merger with Verizon (VZ) is "at least as strategically compelling" as AT&T's (T) deal for Time Warner (TWX), Harrigan thinks that price and regulatory hurdles could be difficult to overcome. He cut his price target on Charter to $350 from $360.
SNAP Snap
$17.33

-0.2112 (-1.20%)

06/07/17
NOMU
06/07/17
NO CHANGE
Target $14
NOMU
Reduce
Snap download trends deteriorated thus far in Q2, says Nomura Instinet
An analysis of app download data from SensorTower points to year-over-year deterioration in Snapchat download trends through the first two months of Q2, Nomura Instinet analyst Anthony DiClemente tells investors in an intraday research note titled "Snap Back Unlikely in 2Q." He points out that Facebook's (FB) Instagram downloads grew year-over-year in Q2, which the analyst believes suggests competitive pressures may be intensifying for Snap. For April and May, SensorTower has Snap worldwide downloads down 22%. DiClemente keeps a Reduce rating on the shares with a $14 price target. He lowered his 2017 earnings per share estimate for SNAP to ($3.24) from ($2.68) and revenue estimate to $842M from $953M. These estimates are well below the consensus. Snap in midday trading is down 73c to $19.63.
06/08/17
OPCO
06/08/17
NO CHANGE
Target $23
OPCO
Outperform
Oppenheimer checks show slower adoption by new advertisers for Snap
Oppenheimer analyst Jason Helfstein says his recent channel checks indicate strong growth in existing advertiser spend for Snap, but slower adoption by new advertisers due to platform-specific video ads, limited 3P data and brand safety concerns for user-generated story ads. As a result, the analyst removed $5M from this Q2 revenue estimate to reflect slower than expected advertiser adoption and added the same amount to his Q4 estimate. He expects all of the new advertiser headwinds to be solved over time. Snap's full roll-out of a self-service ad manager in July should accelerate new advertiser adoption in the second half of 2017, Helfstein tells investors in a research note. He keeps an Outperform rating on the shares with a $23 price target.
06/09/17
SBSH
06/09/17
DOWNGRADE
Target $20
SBSH
Neutral
Snap downgraded to Neutral from Buy at Citi
Citi analyst Mark May downgraded Snap to Neutral and cut his price target for the shares to $20 from $24. The camera company closed yesterday down 4% to $18.85. A slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth, May tells investors in a research note. Further, he believes investors "may continue to be wary near term" of the company's user growth, which disappointed in Q1. The analyst adds that the IPO lock-up expiration in August will increase the stock available for sale by over 500% or 949M shares. He believes this could pressure the stock.
06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

HSIC

Henry Schein

$80.90

-1.98 (-2.39%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Initiation
Henry Schein initiated  »

Henry Schein initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.34

0.26 (0.38%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Recommendations
CarMax analyst commentary  »

CarMax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Periodicals
Portola blood thinner launch could be complicated by guidelines, STAT News says »

The commercial launch of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

CRL

Charles River

$107.29

1.27 (1.20%)

07:35
09/19/17
09/19
07:35
09/19/17
07:35
Initiation
Charles River initiated  »

Charles River initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$85.84

1.04 (1.23%)

, BOBE

Bob Evans

$72.93

1.02 (1.42%)

07:35
09/19/17
09/19
07:35
09/19/17
07:35
Hot Stocks
Post Holdings to acquire Bob Evans for $77.00 per share »

Post Holdings (POST) and…

POST

Post Holdings

$85.84

1.04 (1.23%)

BOBE

Bob Evans

$72.93

1.02 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.